Evolyra Therapeutics

Evolyra Therapeutics, headquartered in Richmond, Virginia, is dedicated to developing transformative gene therapies for rare neuromuscular diseases, with an initial focus on limb-girdle muscular dystrophy (LGMD). The company is advancing a next-generation gene therapy platform based on a muscle-targeting adeno-associated virus (AAV) vector designed to deliver full-length functional genes directly to skeletal muscles while minimizing off-target effects such as hepatotoxicity. This differentiated approach aims to overcome the safety and efficacy limitations observed in earlier gene therapy programs. Evolyra is initially targeting LGMD subtypes 2C and 2D—progressive and currently untreatable conditions that cause severe muscle degeneration and reduced quality of life—but envisions a scalable and modular platform strategy to develop full gene replacement therapies for over 20 LGMD subtypes and potentially other genetic disorders. By collaborating with academic leaders and global patient advocacy groups, Evolyra integrates clinical expertise, translational research, and patient-driven data to accelerate development and enhance trial readiness. Founded by physicians, scientists, and biotech leaders, Evolyra Therapeutics emphasizes a patient-centric model focused on safety, precision, and speed.